INTRODUCTION
Sporadic colorectal cancer (SCRC) includes mali gnancies that occur in the large intestine (colon) and rectum. This type of cancer is the fifth most common cancer in Brazil. In 2016, an estimated 34280 new cases of SCRC will be diagnosed in Brazil, according to a survey conducted by the National Cancer Institute (INCA) [1] . This is the third most common cancer worldwide with an estimated 136100 new cases each year, mainly in developed regions. The overall mortality rate is estimated to be 694000 deaths, 8 .5% of all cases. Fiftytwo percent of these deaths occur in developing regions of the world [2] . The main etiological factors related to SCRC are age over 50 years [1] and tobacco [3] and alcohol consumption [4] . Tobacco and alcohol are environmental carcinogens responsible for the release of exogenous compounds, including reactive oxygenated intermediates (ROMs) represented by benzo[a]pyrene (BaP) Nnitrosamines, heterocyclic amines (HAs) and polycyclic aromatic hydrocarbons (PAHs). These compounds are metabo lically activated in electrophilic forms before interaction with DNA, and they generate adducts and contribute to tumor initiation [5] . The elimination of these environmental carcinogens requires metabolic activation mediated by xenobiotic metabolizing enzymes (XMEs), such as cytoch rome P450 (CYP) and epoxide hydrolase (EPHX1). Polymorphisms in several genes encoding these XMEs are responsible for metabolism errors, which can contribute to the development of several cancer types [57] . In the liver and intestine, Phase Ⅰ oxidative enzymes convert the compounds to highly reactive metabolites by introducing one or more hydroxyl groups in the substrate, increasing its water solubility and converting it into a form that will be more easily expelled. These enzymes, including CYPs and EPHX1, are involved in cellular pathways required for the carcinogenesis process, such as the metabolism of eicosanoids, the biosynthesis of cholesterol and bile acids, steroid synthesis, biogenic amine synthesis and degradation, vitamin D3 synthesis, hydroxylation of retinoic acid, and arachidonic acid metabolism [5, 6, 8] .
Singlenucleotide polymorphisms (SNPs) in genes encoding XMEs can modify the enzyme expression or function and, consequently, alter the activation or detoxification of carcinogenic compounds. The balance between metabolic activation and detoxification can affect the risk of cancer once DNA adducts play an important role in the carcinogenic process [5, 6] . SNPs in the CYP1A1 and CYP2E1 genes, which encode important XMEs, can lead to alterations of the function of these enzymes, resulting in the activation of carcinogens, which are involved in tumor initiation [5] . These polymorphisms have been associated with colorectal cancer development [9, 10] . Among the polymorphisms, the main ones are CYP1A1*2A (rs4646903), resulting in the substitution of thymine for cytosine (T3801C) in the poly (A) tail of the 3' untranslated gene region [11, 12] ; CYP1A1*2C (rs1048943), resulting from the transition of adenine to guanine (A2455G) [13, 14] ; CYP2E1*5B (rs3813867), with the substitution of guanine for cytosine at the 1293 nucleotide position [12, 15] ; and CYP2E1*6 (rs6413432), caused by the alteration of thymine to adenine at position 7632 of the gene [16, 17] . EPHX1 Tyr113His (rs1051740) and EPHX1 His139Arg (rs2234922), functional polymorphisms of the EPHX1 gene, have been well characterized [18] . These polymorphisms are associated with the susceptibility to SCRC [19, 20] . The EPHX1 Tyr113His polymorphism, located at position 337 in exon 3 of the EPHX1 gene, is characterized by a substitution of the amino acid histidine for tyrosine at position 113 of the protein. This change leads to a decrease of approximately 4050% of the enzyme activity and stability in vitro. The polymorphism EPHX1 His139Arg, localized in exon 4 at position 416 of the EPHX1 gene, results in the amino acid substitution of arginine to histidine at position 139 of the protein. These modifications increase the enzyme activity and stability by 25% [18, 21] . In the present study, we investigated the association between the CYP1A1*2A, CYP1A1*2C, CYP2E1*5B, CYP2E1*6, EPHX1 Tyr113His and EPHX1 His139Arg polymorphisms and SCRC risk, the interaction between these polymorphisms with tobacco and alcohol consumption, and the association of SCRC with sociodemographic factors.
MATERIALS AND METHODS

Approval and consent
After approval by the Ethics in Research Commit tee CEP/FAMERP, protocol No. 012/2012 (CAAE: 0237.0.140.00011), the individuals who agreed to participate in the study signed an informed consent form. Information about current and past occupations, tobacco and alcohol consumption, and family history of cancer or adenomatous polyps and lesions were collected using a standard intervieweradministered questionnaire. The ethnicity was not evaluated during this study because of the miscegenation of the studied population.
Study populations
Six hundred twentyseven individuals (227 patients with sporadic colorectal cancer and 400 controls) were included in the study (Table 1) . The recruitment of patients and controls, as well as the collection of peripheral blood and clinical and histopathological data, was performed between 2010 and 2013 at the Coloproctology Service of Hospital de Base/Sao Jose do Rio Preto Medical School, Sao Jose do Rio Preto, SP, Brazil. In the present study, it was not necessary for a followup of the individuals. The case group consisted of individuals with a clinical and histopathological diagnosis of SCRC. The exclusion criteria were patients with hereditary cancer and those previously treated with chemotherapy and/or radiotherapy. The control group consisted of healthy individuals, blood donors with no history of a cancer diagnosis and no family history of cancer in at least three previous generations and other diseases according to the criteria of the American Association of Blood Donors [22] . We considered smoker individuals as those patients who consumed >100 cigarettes in a lifetime. We considered alcohol drinkers as those patients who consumed > 1 drink per week (one drink was defined as approximately 44 mL of liquor or 118 mL of wine or 350 mL of beer) [23] . Tumors were TNM classified according to the following three criteria: the tumor extent (T), the presence of regional lymph node involvement (N) and the presence of distant metastasis (M) [24] . T1 and T2 tumors were classified as smaller tumors, and T3 and T4 tumors were classified as larger tumors. Lymph node involvement was classified according to its absence (N0) and presence (N1, N2, N3). Tumors were classified as nonaggressive (stage Ⅰ and Ⅱ) and aggressive (stage Ⅲ and Ⅳ) according to the clinical staging (TNM) [25] . Information about TNM was impossible in all cases. The analysis of these parameters was performed in a smaller group. Therefore, for the analysis of tumor extension, only 200 samples were analyzed. For the analysis of regional lymph node involvement, 198 samples were analyzed. For the evaluation of aggressiveness, 114 samples were included in the analysis.
Nucleic acid extraction
DNA extraction was performed from peripheral blood leukocytes according to the procedure by Miller and collaborators with modifications [26] . Quantification and the purity of DNA samples were determined by absorbance at a wavelength (λ) at 260 and 280 nm using the Picodrop Pico200 TM spectrophotometer (HWE). The software Minitab, version 16.0, was used to perform the normality test (similar to the Shapiro Wilk method) of the variable age, and a binary logistic regression model was used to evaluate the association between the variables and SCRC and also to evaluate the association of polymorphisms with clinical and histopathological parameters after the adjustment for age, gender, and tobacco and alcohol consumption. The SNPStats software (available at: < http:// bioinfo.iconcologia.net/SNPstats_web>) was used to perform binary logistic regression to evaluate the association of polymorphisms with SCRC risk in the logadditive model (major allele homozygotes vs heterozygotes + minor allele homozygotes with weight 2), the dominant model (major allele homozygotes vs heterozygotes + minor allele homozygotes), the recessive model (major allele homozygotes + heterozygotes vs minor allele homozygotes), the codominant model (heterozygotes vs major allele homozygotes and minor allele homozygotes vs major allele homozygotes), and the overdominant model (major allele homozygotes vs heterozygotes + minor allele homozygotes), after adjustment for age, gender and tobacco and alcohol consumption. The SNPStats program was also used to evaluate the potential interaction between the polymorphisms and tobacco or alcohol consumption, adjusted for the other variables on SCRC risk. The results are presented as odds ratios (ORs) and 95%CI. Linkage disequilibrium between the polymorphism and haplotype frequencies was determined using the Haploview program, version 2.05. Results with a P value < 0.05 were considered statistically significant. The statistical review of the study was performed by a biomedical statistician.
RESULTS
The normality test was performed for the variable age, which had a normal distribution (P < 0.01). Table 1 shows the sociodemographic data of the SCRC patients and controls. Age over 62 years (mean age of the case group; OR = 7.54, 95%CI: 4.9411.50, P < 0.01) (Thermo Scientific).
Polymorphism genotyping
The genotyping of CYP1A1*2A (rs4646903), CYP2E1*5B (rs3813867) and CYP2E1*6 (rs6413432) polymor phisms was performed by polymerase chain reaction restriction fragment length polymorphism (PCRRFLP). The primer sequences used for amplification and the enzymes used to identify polymorphic sites are shown in Table 2 .
EPHX1 Tyr113His (rs1051740) and EPHX1 His139Arg (rs2234922) and CYP1A1*2C (rs1048943) polymorphism genotyping was performed by realtime PCR. The reactions were established according to the manufacturer's protocol (Applied Biosystems) with specific primers and probes validated (TaqMan MGB probes: Assay ID C__14938_30, C__11638783_30 and C_25624888_50, respectively). The reactions were performed using the Step One Plus TM RealTime PCR System (Applied Biosystems).
Statistical analysis
Descriptive statistics included the mean values, standard deviation for continuous data and percentages for categorical data. The BioEstat software, version 5.0 was used to evaluate the HardyWeinberg equilibrium HWE analysis was performed in casecontrol studies to verify if the allele frequency is similar to the expected frequency throughout the generations and to allow the investigation of the association between an allele and pathological conditions. The results of the association between the six polymorphisms with SCRC are shown in Table 4 . CYP2E1*5B and CYP2E1*6 polymorphisms were associated with SCRC in all genotype models, except for the logadditive for CYP2E1*5B because the minor allele was not represented in the control group. CYP1A1*2A, CYP1A1*2C, EPHX1 Tyr113His and EPHX1 His139Arg polymorphisms were not associated with SCRC.
In the present study, the interaction of the presence of polymorphisms and tobacco or alcohol consumption with the SCRC risk was not demonstrated ( Regarding the clinical and histopathological para meters of SCRC, the most common variables were tumor extension T3 and T4 (61.63%), the absence of lymph node involvement (52.91%) and the rectum as the primary site (52.09%). The polymorphisms were not associated with clinical and histopathological parameters (data not shown).
Haplotype analyses were conducted to evaluate the combined effect of the polymorphisms on SCRC development. The CYP1A1*2A and CYP1A1*2C polymorphisms in our study were in strong linkage disequilibrium 
DISCUSSION
The results of the present study showed that indivi duals aged 62 years and older are more susceptible to SCRC, corroborating the data reported by previous studies, which established that age is a risk factor for this disease [1, 10, 19, 20] . We also observed that male subjects were less susceptible to SCRC, although the incidence of SCRC is similar between genders [1, 21] . In the present study, the CYP2E1*5B and CYP2E1*6 polymorphisms were associated with increased SCRC risk. The CYP2E1 haplotypes formed by both minor alleles (CA) were also associated with SCRC. The CYP2E1*5B [10] and CYP2E1*6 [27] polymorphisms can enhance the transcription of the CYP2E1 gene and increase the level of enzyme activity. CYP2E1 is involved in arachidonic acid metabolism, producing hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids, which have been implicated in inflammation and vascular endothelial growth factordependent angio genesis [2830] . Furthermore, CYP2E1 is involved in reactive oxygen species (ROS) production, which is related to angiogenesis induction and metastatic growth of tumor cells [31] . Therefore, the increase in enzyme activity as a result of the CYP2E1 polymorphism may contribute to an increased risk of cancer.
Studies have also shown an association between the polymorphic genotype of CYP2E1*5B (CC) [10, 27, 32, 33] and the polymorphic genotype of CYP2E1*6 (AA) [10, 34] and increased SCRC risk in Caucasians. However, in other studies, these polymorphisms were not associated with SCRC [17, 3436] . The CYP1A1*2A, CYP1A1*2C, EPHX1 Tyr113His and EPHX1 His139Arg polymorphisms were not associated with SCRC risk in the present study. The literature has shown controversial results from the influence of these polymorphisms on SCRC development. Studies in Japanese [37] and Lebanese [35] populations, as well as a recent metaanalysis [38] , did not find an association between the CYP1A1*2A polymorphism and this tumor type. On the other hand, a study conducted in Asia showed that the CYP1A1*2A and CYP1A1*2C polymorphisms increase the SCRC risk in this po pulation [39] . The association of the CYP1A1*2C with SCRC was also evidenced in a study conducted in Hungary [32] and was confirmed in two meta-analyses, especially in Asians and Caucasians [40, 41] . Two other studies conducted in an Asian population, similar to our findings, did not observe the influence of the CYP1A1*2C polymorphism on SCRC [37, 42] . The genotype frequencies of CYP1A1*2A and CYP1A1*2C are in HWE equilibrium in only the case group. According to the literature, casecontrol studies with SNP analysis have shown HWE disequilibrium in patients or controls or in both groups [43] . Regarding the Tyr113His and His139Arg poly morphisms of the EPHX1 gene, our results are consistent with another study from North America that did not find a significant association between these polymorphisms and SCRC [21] . Some studies have shown an association between SCRC and these polymorphisms [19, 20, 36] . A metaanalysis showed that there are differences between studies of different populations that explain the contradictory results. The authors have observed that the allele frequencies of EPHX1 polymorphisms and their effects on cancer risk are different depending on the population studied. Different ethnic compositions, inclusion criteria, the quality of original studies, selection bias and study sample size may contribute to the discrepancy. In this metaanalysis, the EPHX1 Tyr113His polymorphism was not associated with SCRC risk, and the EPHX1 His139Arg polymorphism was associated with decreased SCRC risk [44] .
The present study did not show a potential interaction between the presence of the polymorphisms investigated and tobacco and alcohol consumption concerning SCRC risk. These results agree with the study that evaluated the interaction of these variables with the CYP1A1*2A, CYP1A1*2C, EPHX1 Tyr113His and EPHX1 His139Arg polymorphisms [4547] . On the other hand, an interaction was observed between the CYP1A1*2A, CYP1A1*2C polymorphisms (heterozygous) and tobacco consumption concerning SCRC risk [39] . Huang and colleagues [17] found an elevated risk of SCRC in individuals who were EPHX1 Tyr113His and EPHX1 His139Arg polymorphisms carriers and smokers.
To our knowledge, no study evaluated the interaction between CYP2E1*6 polymorphisms and tobacco and alcohol consumption concerning SCRC risk. Regarding CYP2E1*5B, an interaction between the CYP2E1*5B polymorphism and alcohol consumption concerning SCRC risk was described in the literature [33] . Interestingly, the observation in the present study about the increased SCRC risk in the presence of CYP2E1*5B and CYP2E1*6 polymorphisms, independent of tobacco and alcohol consumption, reinforces the influence of these polymorphisms in the etiology of SCRC.
The most representative primary site in this study was the rectum, corroborating a previous report regarding the higher occurrence of primary SCRC at this anatomical location [48] . The tumor extent and presence of lymph node involvement were not associated with the polymorphisms evaluated during this study. According to our knowledge, there are no studies evaluating the association between these clinical variables and CYP2E1 and EPHX1 polymorphisms in SCRC. The association between the CYP1A1*2A polymorphism and clinical and histopathological data were investigated in lung cancer. However, no association was found [49] .
The discrepancy between these studies may be the result of several variables, such as differences in gender, epidemiological factors and study design. Therefore, further studies are needed to better understand the factors involved in SCRC etiology. A summary of the comparison between our results and the literature data can be observed in Table 6 .
In conclusion, our data demonstrate the influence of the CYP2E1*5B and CYP2E1*6 polymorphisms in SCRC development for the population studied. In addition, individuals aged 62 years and older are more susceptible to the SCRC. Male individuals are less susceptible. These results can contribute to the identification of biomarkers for SCRC and understanding of the mechanisms involved in colorectal carcinogenesis.
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COMMENTS
Background
Colorectal cancer is the third most common cancer worldwide and can be related to altered metabolism of carcinogens. Therefore, it is interesting to evaluate polymorphisms in genes related to this process, such as Cytochrome P-450 (CYP450) and Epoxide hydrolase 1 (EPHX1). Polymorphisms in the genes encoding CYP1A1, CYP2E1, and EPHX1 may alter the levels of gene transcription and enzyme activity. This alteration can lead to DNA damage and the deregulation of mechanisms involved in colorectal cancer.
Research frontiers
Polymorphisms in the genes encoding CYP1A1, CYP2E1, and EPHX1 have been extensively studied in the susceptibility to diseases such as cancer. However, the literature presents conflicting results. Therefore, several studies are necessary to evaluate and confirm the real role among the factors that influence alterations in metabolic processes related during colorectal cancer.
Innovations and breakthroughs
For the first time, a study evaluated the haplotype formed by minor alleles of polymorphisms of the CYP2E1 and CYP1A1 genes in colorectal cancer development. The haplotype formed by minor alleles of polymorphisms CYP2E1*5B and CYP2E1*6 was associated with increased colorectal cancer risk.
Applications
Data showed that carriers of polymorphisms CYP2E1*5B and CYP2E1*6 constitute a risk group for sporadic colorectal cancer (SCRC). Thus, considering the high incidence of this cancer, it is important for the comprehension of the factors that lead to carcinogenesis for the development of preventive and therapeutic strategies for cancer management.
Terminology
CYP1A1: Cytochrome P-450 CYP1A1 (cytochrome P450 family 1 subfamily A member 1), gene located on chromosome 15 (NC_000015.10). CYP2E1: Cytochrome P-450 CYP2E1 (cytochrome P450 family 2 subfamily E member 1), gene located in chromosome 10 (NC_000010.11). EPHX1: Epoxide Hydrolases 1, gene located in chromosome 1 (NC_000001.11).
Peer-review
Fernandes et al have conducted a very good case control study examining the involvement of CYP1A1, CYP2E1, and EPHX1 polymorphisms in SCRC. They find age over 62, female gender, CYP2E1*5B and CYP2E1*6 polymorphisms associated with SCRC.
